SHLP2 and SHLP6 are each a peptide that works inside your mitochondria.
| Comparison | SHLP2 small humanin-like peptide 2 · SHLP-2 | SHLP6 small humanin-like peptide 6 · SHLP-6 |
|---|---|---|
| How it works | How it works SHLP2 comes from the same discovery programme as humanin and MOTS-c, both of which this library already covers. | How it works The six SHLPs were found together and behave differently, which is the single most useful fact about them. |
| What it is | A mitochondrial peptide with real published biology and no human dosing behind it. | The sibling of SHLP2, and the one reported to shut blood vessel growth down. |
| Status | Research only | Research only |
| Typical dose | — | — |
| How often | Not established | Not established |
| Stays active | Nothing published | Nothing published |
| Dose comes from | No established range | No established range |
| Cycled? | Not established No established range | Not established No established range |
| What it does | ||
| Drug class | Mitochondrial-derived peptide | Mitochondrial-derived peptide |
| Used for | A mitochondrial peptide researched for insulin sensitivity, mitochondrial function and aging. | A mitochondrial peptide researched for oxidative stress and cell protection. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | Research only | Research only |
| Why that cycle | No schedule has been studied for this compound in people. | No schedule has been studied for this compound in people. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | Not disclosed | Not disclosed |
| Common vial | — | — |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | Pregnancy or breastfeeding Active cancer, as a precaution with anything affecting cell survival signalling Anyone who wants established safety data, because none exists for this compound in humans | Pregnancy or breastfeeding Active wound healing or recovery from surgery, given the reported effect on blood vessel formation Active cancer, without oncology advice Anyone who wants established safety data, because none exists for this compound in humans |
What separates them
Proof behind the dose. Every dose here comes from community practice. Not one is backed by a published human study, which is worth knowing before you read the numbers as if they were equivalent.
What doesn't differ: They are both taken the same way (under the skin), aimed at the same thing (metabolic & aging) and on the same schedule (not established). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
SHLP2
- All published work is in cells and animals.
- No human study of administering it has been published.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Redness, heat, or pus at the injection site, which can signal infection
SHLP6
- All published work is in cells and animals.
- It has been reported to inhibit new blood vessel formation, which matters if you are healing something.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Redness, heat, or pus at the injection site, which can signal infection
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.